Slide 1: Investor Presentation September 2026
For personal use only Investor Presentation September 2026 Developing new therapies to treat kidney Authorised for lodgement by the Board of the Company diseases with unmet clinical needs
Slide 2: Forward looking statements
Forward looking statements This presentation includes forward-looking statements that are subject to risks and uncertainties. Although we believe that the expectations reflected For personal use only in the forward looking statements are reasonable at this time, Dimerix can give no assurance that th
Slide 3: DMX-200: Phase 3 Global Opportunity
DMX-200: Phase 3 Global Opportunity For personal use only 5 commercial up to $1.9 billion Phase 3 trial FSGS indication Reduced risk Orphan drug partners in total recruitment is a rare disease Proteinuria endpoint passed blinded designations DMX-200 licensed development and complete in that causes s
Slide 4: Cycle of damage in glomerular diseases
Cycle of damage in glomerular diseases What is FSGS? Existing blood pressure medication For personal use only Glomeruli exposed to stress from high blood pressure DMX-200 Focal = some 1 Segmental = sections High blood pressure causes hyperfiltration Glomerulo = of the kidney filtering units within f
Slide 5: Interpreting proteinuria as a surrogate endpoint
Interpreting proteinuria as a surrogate endpoint Proteinuria is the quantity of protein in the urine Proteinuria as a predictor of kidney disease3 For personal use only A healthy kidney is a good filter and allows little to no protein into Dip test uPCR g/g the urine1 NORMAL Neg <0.13 normal Inside
Slide 6: Phase 3 ACTION3 clinical trial design
European Renal Association Posters 2025 phase 3 clinical trial A randomised, double-blind, multi-centre, placebo-controlled study of renal outcomes of DMX-200 in patients with FSGS receiving an ARB (n=≥286) For personal use only Background Phase 3 Trial Timeline Open Label Extension Successful inter
Slide 7: Adult patient recruitment by territory
adult patient recruitment by territory For personal use only Trial designed for potential approval globally Recruitment completed (adult population)1 333 Adult patients recruited, randomised and dosed (target ≥286)2 Latin America Asia Pacific US / Europe 1. ASX release 15 December 2025; 2. Final num
Slide 8: Competitive/complementary trial landscape in FSGS
Competitive/complementary trial landscape in FSGS Low competition in inflammatory treatment options, large unmet medical need For personal use only DMX-200 is the only inflammatory modulator in development specifically for FSGS DMX-200 has potential for use in conjunction with other drugs in develop
Slide 9: Summary of licensing deals for DMX-200 to date
Summary of licensing deals for DMX-200 to date Dimerix has successfully partnered DMX-200 across multiple key markets For personal use only Licensing deals collectively 1 2 3 4 5 valued up to ~AU$1.9 United States China,S.Korea.SEA EU, CA, AU, NZ Japan GCC, Iraq billion AU$48 million1 AU$14.1 AU$10.
Slide 10: DMX-200 - geographic diversification of fee revenue
DMX-200 - geographic diversification of fee revenue Collectively, five commercial agreements valued up to A$1.9 billion across upfront + milestone fees:1 For personal use only On signing Short Term Potential Longer Term Potential Upfront fees Milestone Payments Milestone Payments Royalties Diversifi
Slide 11: DMX-652 in Acute Kidney Injury
For personal use only DMX-652 in Acute Kidney Injury
Slide 12: DMX-652: Phase 2 in acute kidney injury
DMX-652: Phase 2 in acute kidney injury A complementary, clinical-stage pipeline addition value potentialuse only Leverages existing expertise Strategic value Large and growing market First and best in class personal • Secured a Phase 2 ready • First-in-class USP30 • Dimerix team are experts • No ap
Slide 13: Introducing DMX-652
Introducing DMX-652 A first-in-class, oral, once-daily USP30 inhibitor for the prevention of acute kidney injury in high-risk patients undergoing cardiac surgery For personal use only Small molecule Once-daily dosing Well tolerated Phase 2 ready New chemical entity; oral Convenient dosing schedule t
Slide 14: What is AKI associated with cardiac surgery
What is AKI associated with cardiac surgery Currently no approved disease-modifying therapies For personal use only 1 Cardiac Surgery 2 Ischaemia 3 Reperfusion: restores blood flow to kidney Mitochondria rupture Healthy mitochondria ~26% of patients undergoing cardiac surgery suffer kidney injury; i
Slide 15: How DMX-652 works – unique, novel mechanism
How DMX-652 works – unique, novel mechanism DMX-652 aims to enable the body's natural quality-control system to remove damaged mitochondria (a process called mitophagy) before they trigger kidney cell death For personal use only Healthy kidney Acute Kidney Injury (AKI) DMX-652 targets USP30 Damaged
Slide 16: DMX-652 Pre-clinical data demonstrates efficacy signal
DMX-652 Pre-clinical data demonstrates efficacy signal DMX-652 reduces kidney damage DMX-652 reduces scarring (fibrosis) • The uIRI model replicates the processes of • The UUO model predicts acute to chronic For personal use only cardiac surgery that cause AKI kidney disease progression. • DMX-652 s
Slide 17: Proposed Phase 2 clinical trial design
Proposed phase 2 clinical trial design A multicentre, double-blind, randomised, placebo-controlled study evaluating the safety and efficacy of DMX-652 in patients at high risk of AKI following cardiac surgery (n=160) For personal use only Screening/randomisation Treatment phase Follow up • Patients
Slide 18: Significant unmet need in AKI
Significant unmet need in AKI With no approved disease-modifying therapies, severe consequences for patients, surgeons, and health systems For personal use only 0 1 in 4 30-50% No approved therapies for the Cardiac surgery patients AKI rate in high-risk patients prevention of cardiac surgery- develo
Slide 19: Competitive/complementary trial landscape in AKI
Competitive/complementary trial landscape in AKI DMX-652's differentiated mechanism of action supports complementary use and the potential for superior or additive outcomes For personal use only Cellular ischaemia Mitophagy Unicycive Therapeutics modulator Phase 1 UNI-494 Mitochondrial K-ATP channel
Slide 20: DMX-200 and DMX-652: complementary growth pillars
DMX-200 and DMX-652: complementary growth pillars Strategic fit: shared renal capabilities, shared regulatory/clinical infrastructure, shared small-molecule know-how For personal use only DMX-200 DMX-652 Focal Segmental Glomerulosclerosis Acute kidney injury associated with (FSGS) rare kidney diseas
Slide 21: Key potential value inflection points
Key potential value inflection points Disciplined, stage-gated capital deployment focused on the clinical value inflection1 For personal use only Paediatric recruitment completion; first patient completes open label Phase 3 ACTION3 NDA dossier submission extension study IDMC safety review Phase 3 FS
Slide 22: Corporate overview
Corporate overview S H A R E P R I C E Ticker Symbol ASX: DXB For personal use only Cash Balance (Jun26)* $16.2 million Market Capitalisation1 $174 million Share price1 $0.29 Total ordinary shares on issue1 600,396,776 Average Daily Liquidity by value for $0.85 million past 90 trading days2 S UBSTA
Slide 23: ESG Statement
(ASX:DXB) For personal use only A biopharmaceutical company developing innovative new therapies in areas with unmet medical needs, with a core focus on kidney diseases. W E L L P O S I T I O N E D TO D E L I V E R AGA I N ST ST R AT EG I C P L A N ESG Statement Dimerix is committed to integrating En
Slide 24: DMX-200 – inflammatory modulator
DMX-200 – inflammatory modulator For personal use only A CCR2 inhibitor working synergistically alongside the current standard of care (AT1R blocker): G protein-coupled receptor (GPCR) Commercial manufacturing sites established in USA3 1. ASX release and investor presentation 29Jul20 and ASX release
Slide 25: DMX-200: unique pharmacology
DMX-200: unique pharmacology • CCR2 activation promotes recruitment of inflammatory 500 Proteinuria (mg/24hours) monocytes to the kidney 400 For personal use only 300 DMX-200 inhibits CCR21 200 Simultaneous inhibition of * CCR2 and AT1R reduces 100 proteinuria an important • Monocytes promote sclero
Slide 26: DMX-200: Phase 2 met primary endpoint
DMX-200: Phase 2 met primary endpoint Clinically encouraging outcomes achieved for patients,1,2 with no safety concerns noted3 For personal use only Average reduction of 17% in proteinuria after 16 weeks treatment on DMX-200 versus placebo3 “Any reduction in proteinuria could yield years of preserve
Slide 27: DMX-200 Phase 2 effect on inflammatory biomarker
DMX-200 Phase 2 effect on inflammatory biomarker1 Unlike other CCR2 antagonists investigated to date, treatment with DMX-200 reduces the urine concentration of the pro-inflammatory ligand of CCR2 called MCP-12 For personal use only Average baseline MCP-1 versus Change in MCP-1 over time on average b
Slide 28: DMX-200 intellectual property portfolio
DMX-200 intellectual property portfolio DMX-200 For personal use only Exclusivity Portfolio 3 7/10 years Exp.2042 Orphan exclusivity from (if granted) marketing approval date in many territories1 Portfolio 2 Formulation Portfolio 5 Global application3 + Exp.2042 Exp.2045/6 (if granted) Paediatric (i
Slide 29: DMX-652 Phase 1 study met primary endpoint
DMX-652 Phase 1 study met primary endpoint Completed in healthy volunteers: strong safety & pharmacokinetic foundation to support Phase 2 clinical trial For personal use only 85 0 Up to 200mg 100mg Healthy volunteers No serious adverse events Single dose well tolerated; Once daily x 14 days; receive
Slide 30: DMX-652: first-in-class, best-in-class potential
DMX-652: first-in-class, best-in-class potential Unlike competing programs targeting specific inflammatory or fibrotic pathways, DMX-652 acts on a downstream, convergent driver of kidney injury — making it applicable across causes of AKI For personal use only 1 3 Only USP30 inhibitor in clinical dev
Slide 31: DMX-652 - significant unmet need in AKI
DMX-652 - significant unmet need in AKI With no approved disease-modifying therapies, severe consequences for patients, surgeons, and health systems For personal use only 0 1 in 4 30-50% No approved therapies for the Cardiac surgery patients AKI rate in high-risk patients prevention of cardiac surge
Slide 32: DMX-652 Intellectual property
DMX-652 Intellectual property DMX-652 The acquisition secures owned composition-of-matter IP, plus exclusive freedom-to-operate rights and regulatory exclusivity For personal use only ACQUIRED · ASSIGNED TO DIMERIX Composition-of-matter patent family 2041 19 Directly covers DMX-652 (originally MTX-6
Slide 33: Dimerix board
Dimerix board For personal use only Previous experience: Previous experience: Previous experience: Previous experience: Previous experience: (2) (1) (Faulding)(1) • Senior pharmaceutical executive • Experienced in product • Extensive biotech drug • Experienced executive in • Experienced technology a
Slide 34: Dimerix management
Dimerix management For personal use only Previous experience: Previous experience: Previous experience: Previous experience: (1) • Experienced in product • Experienced finance and • 35 years international experience • Experienced pharmaceutical development, commercial strategy governance executive w
Slide 35: Medical Advisory Board
Medical Advisory Board For personal use only Professor of Clinical Trials and Professor of Medicine & Mayer Professor of Renal An attending physician and Renal Physician and Head of Graduated from Haverford Assistant Professor in the Personalized Medicine: Molecular & Cellular Medicine: Department o